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Abstract
Background: There is growing evidence of the treatment efficacy of cognitive behavioral therapy (CBT) for irritable
bowel syndrome (IBS). CBT is recommended by several practice guidelines for patients with IBS if lifestyle advice or
pharmacotherapy has been ineffective. Manual-based CBT using interoceptive exposure (IE), which focuses on the
anxiety response to abdominal symptoms, has been reported to be more effective than other types of CBT. One
flaw of CBT use in general practice is that it is time and effort consuming for therapists. Therefore, we developed a
set of complementary video materials that include psycho-education and homework instructions for CBT patients,
reducing time spent in face-to-face sessions while maintaining treatment effects. The purpose of this study is to
examine the effects of CBT-IE with complementary video materials (CBT-IE-w/vid) in a multicenter randomized
controlled trial (RCT).
Methods: This study will be a multicenter, parallel-design RCT. Participants diagnosed with IBS according to the Rome
IV diagnostic criteria will be randomized to either the treatment as usual (TAU) group or the CBT-IE-w/vid + TAU group.
CBT-IE-w/vid consists of 10 sessions (approximately 30min face-to-face therapy + viewing a video prior to each
session). Patients in the CBT-IE-w/vid group will be instructed to pre- view 3- to 13-min videos at home prior to each
face-to-face therapy visit at a hospital. The primary outcome is the severity of IBS symptoms. All participants will be
assessed at baseline, mid-treatment, post-treatment, and follow-up (3 months after post assessment). The sample will
include 60 participants in each group.
Discussion: To our knowledge, this study will be the first RCT of manual-based CBT for IBS in Japan. By using psycho-
educational video materials, the time and cost of therapy will be reduced. Manual based CBTs for IBS have not been
widely adopted in Japan to date. If our CBT-IE-w/vid program is confirmed to be more effective than TAU, it will
facilitate dissemination of cost-effective manual-based CBT in clinical settings.
(Continued on next page)
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Introduction
Irritable bowel syndrome (IBS) is a common chronic
functional gastrointestinal disorder that affects about
14% [1] of the Japanese population. Symptoms of IBS
such as abdominal pain and altered bowel habits (i.e.,
constipation and/or diarrhea) interfere with the patient’s
quality of life (QOL) [2] and social functioning [3, 4].
IBS is associated with a significant increase in time off
work [5] and increased health care use. Severity of
abdominal pain/discomfort is a significant predictor
of health care use for patients with IBS compared
with non-IBS subjects [6]. Annual medical expenses
paid for patients with IBS were reported to be 50%
higher than those for population-controlled non-IBS
patients [7].
Evidence for IBS treatment efficacy using cognitive
behavioral therapy (CBT) has been growing [8–10]. Sys-
tematic reviews and meta-analysis have repeatedly con-
firmed CBT efficacy for IBS [11, 12]. Treatment
guidelines issued by the National Institute of Clinical
Excellence (NICE) in the United Kingdom recommend
introducing CBT if lifestyle advise or pharmacotherapies
have been ineffective and symptom duration has exceeded
12months [13]. Specific psychotherapies including CBT
are also recommended in the clinical guideline issued by
the Japanese Society of Gastroenterology as the third step
of IBS treatment that has been refractory to the first step
(lifestyle advise and gut-targeted pharmacotherapies) and
second step (psychopharmacological agents and brief
psychotherapies) treatments [14]. However, CBT for
IBS is available only in specific centers in Japan and
evidence of its efficacy has not been established here.
Therefore, RCT evidence of efficacy for CBT for
patients with IBS is needed.
Among the several CBT programs reported for IBS,
we adopted the interoceptive exposure-based CBT pro-
gram (CBT-IE) for IBS developed by Craske et al. [15].
CBT-IE for IBS includes exposure to abdominal sen-
sations in addition to psychoeducation, self-monitoring,
cognitive restructuring, attention training, and in vivo
exposure, which are often used in traditional CBT.
Patients are exposed to self-induced abdominal sensations
(e.g., by tightening abdominal muscles, or consuming
avoided foods, etc.) to reduce anxiety in response to
abdominal disturbance common in IBS.
Interoceptive exposure (IE) was originally developed
for panic disorder [16], and its clinical applications have
been expanded. IE is considered to weaken the fear
response by enabling new learning that competes with
the initial fearful associations [17]. It has been suggested
that gastrointestinal symptom-specific anxiety (GSA) is
important in perpetuating IBS. GSA has been shown to
predict symptom severity and QOL in IBS. The effect on
IBS symptoms and QOL of interventions using exposure
that targets GSA has been supported by previous studies
[18, 19], and its superiority over active treatment con-
trols has been shown in some RCTs [15, 20].
Our single-arm feasibility study of CBT-IE for Japanese
IBS patients [21] indicated significant reduction of IBS
symptoms and remarkable improvement in IBS-specific
QOL at post-intervention, 3-month, and 6-month follow-
ups compared with the pre-intervention state. Although
CBT-IE appears to be a promising treatment for refractory
IBS, there are some difficulties in disseminating this inter-
vention to clinical settings in Japan, including the limited
number of CBT therapists and the highly time-consuming
process of CBT [11].
To reduce the implementation costs, we developed a
set of complementary video materials that cover psy-
choeducation and homework instructions regarding
treatment so that patients can prepare at home for the
subsequent in hospital, face-to-face therapy. The treat-
ment procedures and contents are the same as with the
original CBT-IE. Our additional feasibility study in-
dicated that use of the video material with CBT-IE
reduced the time spent in face-to-face therapy by about
40% on average, while treatment effectiveness remained
constant. We calculated effect sizes (Hedges’ g) for
changes in the Japanese version of the IBS Severity Index
(IBS-SI-J) before and after the CBT-IE intervention. The
effect size of our first feasibility study of face-to-face
therapy alone [21] was g = − 1.02 (N = 20, session time:
66 ± 7min), and the effect size of our second feasibility
study using video material [22] was g = − 0.99 (N = 8,
session time: 38 ± 7min).
Research objectives and hypotheses
An RCT will be done to examine the efficacy of CBT-IE
with complementary video material (CBT-IE-w/vid) for
Japanese patients with moderate to severe refractory IBS
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patients. The hypothesis is that participants allocated to
the CBT-IE-w/vid + TAU group will have significantly
reduced symptoms compared to the participants in the
TAU alone group.
Methods
This multicenter RCT will be conducted by a multi-
disciplinary team of medical doctors who specialize in
psychosomatic medicine and functional gastrointestinal
disorders, clinical psychotherapists, researchers, and
statisticians.
Design
A multicenter randomized controlled trial with two equal-
sized parallel groups at five centers.
Potential participants will be screened for eligibility
and will give written informed consent to participate.
All participants will be assessed at baseline and then
individually randomized into the CBT-IE-w/vid + TAU
or TAU alone groups. Participant flow is depicted in
Fig. 1.
All assessment measures, except for screening, are
self-report questionnaires. Participants will complete
baseline (pre-treatment), mid-treatment, post-treatment,
and 3-month follow-up assessments. This protocol has
been reviewed and approved by the Institutional Review
Board of the National Center of Neurology and Psychiatry
(accepted on November 29, 2017; A2017–067) and by
the Ethics Committees of the four other collaborating
facilities. The trial has been registered in the University
Fig. 1 Flow of participants through the study
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Hospital Medical Information Network (UMIN) Cli-
nical Trials Registry (URL: http://www.umin.ac.jp), No.
UMIN000030620.
Setting
Participants assigned to the CBT-IE-w/vid + TAU group
will receive the standard IBS treatment from a medical
doctor and face-to-face CBT-IE sessions with a therapist
(a clinical psychotherapist or medical doctor who spe-
cializes in psychosomatic medicine) at a hospital. In
addition, participants in the CBT-IE group will be
instructed to watch the complementary video material
and complete homework at home. Participants in the
TAU alone group will receive the standard IBS treatment
from a medical doctor at the hospital.
The intervention will be conducted at outpatient units of
the five collaborating hospitals: National Center Hospital,
National Center of Neurology and Psychiatry, Tohoku
University Hospital, the University of Tokyo Hospital,
Center Hospital of the National Center for Global Health
and Medicine, and Kohnodai Hospital, National Center for
Global Health and Medicine in Japan.
Target population
Participants will be recruited from the five hospitals listed
above and will include 120 outpatients aged 16 years or
older with an IBS diagnosis according to the Rome IV
diagnostic criteria and moderate to severe IBS symptoms
based on IBS-SI-J scores.
Recruitment
Recruitment will be conducted at each center by adver-
tising and referrals from health care professionals. When
a health care professional deems CBT-IE-w/vid feasible
for the patient, the patient will be informed of this trial
and referred to the trial team of each center.
Screening
The initial screening will be conducted by medical doc-
tors of the trial team of each center, all of whom
specialize in psychosomatic medicine. After the patients
give informed consent, eligibility will be evaluated ac-
cording to the inclusion and exclusion criteria. Eligible
participants will be provisionally registered, subjected to
the baseline outcome assessment, and then definitively
registered.
Eligibility criteria
Inclusion criteria
To be eligible to participate in this study, a participant
must meet all of the following criteria:
1. Aged 16 years or older with IBS that is refractory to
standard pharmacotherapy
2. Diagnosed with IBS based on the Rome IV
diagnostic criteria [23]
3. The severity of IBS is moderate or severe (IBS-SI-J
score: 175 or over) [24, 25]
4. Able to understand the purpose and contents of
this trial and give voluntary written informed
consent
Exclusion criteria
A potential participant who meets any of the following
criteria will be excluded from participation:
1. Organic disease suggested by the presence
of warning symptoms
2. A history of concomitant inflammatory
bowel disease, malignant tumor, or other
bowel disease which could cause the current
bowel symptoms
3. A comorbidity of major psychiatric disease, such
as psychotic disorders, bipolar disorder, substance
abuse-related disorders, eating disorders, obsessive
and compulsive disorders, or PTSD. However,
persons with anxiety disorders, somatic symptoms,
related disorders, or depression without suicidal
ideation will not be excluded. The screening for this
part will be conducted using the Mini International
Neuropsychiatric Interview (M.I.N.I.) [26], a widely
used structured diagnostic interview that screens
for various mental diseases.
4. Antisocial personality disorders
5. Significant suicidal ideation at screening
6. Past or present psychiatric or physical disease that
is likely to interfere with continuation and
evaluation of the study
7. Any other type of marked chronic pain
8. Taking narcotic analgesics
9. Difficulty in attending 10 sessions as an outpatient
during the 16-week CBT implementation period
10. Previously received structured individual CBT
11. Unable to understand verbal and written
communication in the Japanese language
12. Pregnant or lactating women
13. Any other person whom the principal investigator
has determined to be unsuitable as a participant of
the study
Warning symptoms list:
 Symptoms that first appeared after 50 years of age
 Any rectal bleeding that has not undergone
sufficient medical investigation (excluding that
caused by known hemorrhoids)
 Diarrhea-predominant IBS in which no colonoscopy
investigation has been conducted
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 Unexplained weight loss without a change in
eating habits
 Nocturnal symptoms sufficient to cause insomnia
 The presence of warning findings (anemia, positive
inflammatory reactions, or positive fecal occult
blood)
 Persons with a family history of colon cancer
in a first- or second-degree relative (grandparents,
parents, siblings, or children)
Participant withdrawal of consent
Participants can withdraw at any time without penalty.
Withdrawal information will be collected.
Randomization
Randomization will be conducted using the Electronic
Data Capture System (HOPE eACReSS, Fujitsu ltd.),
which can be accessed from each institute via the Internet.
The Electronic Data Capture System will be set up and
managed independent of the study by the Data Manage-
ment division at the National Center of Neurology and
Psychiatry (NCNP). A random sequence will be generated
using stratified randomization by hospital. Eligible partici-
pants will be registered at each hospital on a PC terminal
connected to the Electronic Data Capture System via the
Internet. Allocation to the treatment or control group will
be implemented centrally and automatically upon regis-
tration and then displayed on the terminal.
Planned interventions
CBT - interoceptive exposure with complementary video
materials (CBT-IE-w/vid)
Participants receive CBT using interoceptive exposure
for IBS with complementary psychoeducational video
materials (CBT-IE-w/vid). The original IE program [15]
consists of 10 weekly sessions of approximately 60 min.
Our CBT-IE-w/vid intervention consists of 10 weekly
sessions, but the time length of each session has been
changed. Each session consists of 2 parts: viewing 3- to
13-min videos at home in advance followed by about
30-min of face-to-face therapy session with a therapist
at hospital. All CBT-IE-w/vid therapists will be medical
doctors who specialize in psychosomatic medicine or psy-
chologists qualified in least one of the following: licensed
by the Japanese government, clinical psychologists quali-
fied by the Foundation of the Japanese Certification Board
for Clinical Psychologists, or medical psychologists quali-
fied by the Japanese Society of Psychosomatic Medicine.
CBT-IE-w/vid intervention includes (a) education that
IBS symptoms reflect conditioned reactions to reminders
of gastrointestinal distress (e.g., food intake or a ride on a
train); (b) self-monitoring of IBS symptoms; (c) attentional
control skills to learn to shift attention away from rather
than perseverate upon unpleasant visceral sensations [27];
(d) cognitive therapy to identify threat-laden appraisals of
disturbance caused by IBS symptoms; (e) interoceptive
exposure involving repeated exposure to visceral sensa-
tions (e.g., tightening stomach to produce gut sensations,
delaying entrance to the bathroom, eating feared/avoided
foods) to reduce fear of the sensations; and (f) in vivo
exposure to feared/avoided situations in which IBS sen-
sations were expected (e.g., riding a long-distance train,
eating at restaurants, going places where bathrooms are
not accessible) while weaning “safety signals” or “safety
behaviors” (e.g., keeping medicines handy at all times or
carrying additional underclothing). Reliance on safety sig-
nals or safety behavior during exposure practices inter-
feres with relearning. Homework, using a paper-based
textbook, is required for each session. Table 1 shows the
contents of each session, the handout (including home-
work), and the duration of each video. There is no object-
ive control over the usage of the complimentary video
materials. The videos continue to be available after the
end therapy, as are texts and materials. Patient usage of
video material and homework will be tracked using a
compliance check sheet during intervention and at follow
up.
Treatment as usual (TAU)
Patients in both treatment arms will receive TAU by
medical doctors. TAU is defined as standard treatment
for IBS as recommended by the clinical practice guide-
lines of the Japanese Society of Gastroenterology [14].
According to the guidelines, a three-step strategy is
adopted. The first step consists of lifestyle modification
and gut-targeted pharmacotherapy for approximately 4
weeks. Non-responders to the first step intervention
proceed to the second step, which includes psychophar-
macological agents and brief psychotherapy in addition
to the first step interventions for approximately 4 weeks.
In the third step, for patients who have not obtained
sufficient improvement by the second step, specific
psychotherapies including CBT are recommended.
In this study, TAU will consist of only the first and
second step interventions. Time spent in each TAU
session is 15–30min. The frequency of TAU sessions is
usually once every 4 weeks, but it may vary depending
on the patient’s schedule. There is no limit for duration
of TAU in either arm. This procedure will be beneficial
and ethically desirable for patients.
The medical doctor in charge will implement TAU
using the common guidance reviewed by IBS experts
(SF, KY, and Hiroe Kikuchi).
Quality assurance
To ensure treatment fidelity, CBT-IE-w/vid therapists
will have completed designated CBT-IE-w/vid training
and will receive continuous support from supervisors
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(TA, YF) and peer-supervisors (MF, H Kawanishi)
throughout the study. All CBT-IE-w/vid sessions will be
subject to evaluations of treatment adherence and com-
petence using treatment manuals that provide detailed
session-by-session guidance to standardize interven-
tion among all therapists, who will complete check-
lists for session protocols after each session.
Therapists will rate patient adherence to homework
using a six-point scale [10].
Discontinuation
Any participant who meets any of the following dis-
continuation criteria will have their intervention
stopped. When possible, subsequent assessment will
be conducted.
1. Participant requests discontinuation or participant
withdraws consent
2. Difficulty continuing the intervention because of a
serious adverse event
3. Participant proves after assignment not to fulfill the
eligibility criteria
4. Participant with suicide risk
5. Any other reason that the primary investigator, the
medical doctor, CBT-IE-w/vid therapist, supervisor,
or the Data and Safety Monitoring Board agree
warrants discontinuation
6. The entire clinical trial is stopped
Measures
Primary outcome measure
1. Japanese version of the IBS severity index
(IBS-SI-J): IBS-SI or IBS severity scoring system
(IBS-SSS) was developed in the UK and is widely
used to assess the severity of lower gastrointestinal
symptoms and the degree to which the quality of life
is impaired by IBS. IBS-SI-J is a valid, reliable, and
appropriate instrument for detecting and assessing
the severity of IBS status in Japanese patients
[24, 25]. This self-report instrument has five
items that score abdominal pain, abdominal
distention, bowel movements, and quality of life.
The total score ranges from 0 to 500. IBS
severity is graded as mild (75–174), moderate
(175–299), or severe (300–500).
Table 1 Contents of each session
Session number Contents of intervention Handouts Play time of Video
1 Education about IBS and psychological
stress on digestive functioning,
awareness-raising
• Personal IBS profile (in session use) (12′ 16″)
• Monitoring IBS distress
2 Education about the role of conditioning
in IBS, attentional training
• Monitoring IBS distress (6′ 44″)
• Guide for Attentional training
• Common IBS symptom appraisal list
3 Attentional training, cognitive restructuring
for IBS sensations and risk estimates
• Monitoring IBS distress (9′ 31″)
• Common IBS symptom appraisal list
4 Cognitive restructuring for symptoms of
IBS, valence estimates, hierarchy
construction for IBS sensation reminders
• Monitoring IBS distress (9′ 05″)
• Deliberate exposure hierarchy
5 Cognitive restructuring, interoceptive
exposure assessment, in vivo exposure
• Monitoring IBS distress (11′ 36″)
• Interoceptive exposure exercises
• Interoceptive exposure FAQ
• Guide for IBS and in-vivo exposure
• In-vivo exposure instructions
• Deliberate exposure record
6–9 Conduct of Interoceptive exposure,
in vivo exposure
• Monitoring IBS distress (5′ 40″)
• Interoceptive exposure instructions (3′ 32″)
• Interoceptive exposure record (3′ 43″) (3′ 35″)
10 Interoceptive exposure, in vivo exposure,
summary of the all sessions, relapse
prevention
• Monitoring IBS distress (7′ 44″)
• Relapse prevention Map
• Dealing with setbacks
• List of positive Accomplishments
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Secondary outcome measures
1. Visceral Sensitivity Index (VSI). The VSI assesses
gastrointestinal symptom-specific anxiety [28, 29].
It consists of 15-items scored with a six-point Likert
scale, with items such as “When I feel discomfort in
my belly, it frightens me.” Lower scores indicate
more severe anxiety for abdominal symptoms.
2. Japanese version of the Irritable Bowel
Syndrome Quality of Life Scale (IBS-QOL-J). The
IBS-QOL-J assesses disease-specific QOL for IBS
[30]. It consists of 34 items scored with a five-point
Likert scale. Items ask how IBS affects the daily
functioning of the participant. It includes eight
subscales: dysphoria, interference with activity, body
image, health worry, food avoidance, social reaction,
sexual concerns, and relationships.
3. IBS Diary modified for weekly use. The IBS Diary
[31], which was modified for weekly use, records
stool form types and frequencies, abdominal
symptom severity scores (e.g., pain/discomfort
rated on a 10-point ordinate scale), subjective
feelings of stress, medication adherence, and
the number of times “medicines to be taken as
needed” were used in a week.
4. Irritable Bowel Syndrome Global Improvement
Scale (GIS). The GIS assesses participants’
subjective improvement [32] scored on a
seven-point Likert scale that ranges from 1
(substantially improved) to 7 (substantially worse).
5. MOS 36-Item Short-Form Health Survey (SF-36).
The SF-36 assesses health related QOL and consists
of 36 items [33] that measure eight health concepts:
physical functioning, physical role, bodily pain,
general health, vitality, social functioning, emotional
role, and mental health.
6. Beck Depression Inventory-II (BDI-II). The
BDI-II assesses the existence and severity of
depression symptoms, such as sadness and suicidal
ideation [34, 35]. It consists of 21-items scored on
a four-point Likert scale.
7. State-Trait Anxiety Inventory (STAI). The STAI
assesses state and trait anxiety [36, 37] and consists
of 40-items scored on a four-point Likert scale.
8. Japanese Version of the Body Vigilance Scale
(BVS-J). The BVS-J assesses attention to bodily
sensations [38]. It consists of four items, three of
which assess the degree of attentional focus,
perceived sensitivity to changes in bodily sensations,
and the average amount of time spent attending
to bodily sensations. The fourth item involves
separate ratings for attention to 15 bodily
sensations (e.g., heart palpitations, abdominal
discomfort).
9. Cognitive Control Scale. The Cognitive Control
Scale assesses the degree of cognitive control [39]
and consists of 12 items, scored on a four-point
Likert scale, that ask about thoughts that occur
during a disturbing event. This scale has a
two-factor structure, “analysis of thought and
behavior” and “reframing.”
10. Medication changes. Medication changes include
an additional or increased dose of any drug other
than sleeping drugs and “medicines to be taken as
needed” in response to a participant request or
worsening disease. Medication change data will be
recorded from the start of intervention.
Table 2 shows the schedule of assessments of
outcomes.
Sample size
We estimated a sample size of 60 per group (total 120)
from standardized treatment effects that were estimated
as 0.91 to 1.02 based on the single-arm feasibility study
that preceded this study [21]. However, we used a con-
servative estimate of 0.6 for the standardized treatment
effects for between-group differences because the pre-
vious randomized control trial [15] with a similar target
population and outcomes estimated standardized treat-
ment effects at 0.33 to 0.70. Thus, the minimum re-
quired sample size with minimum power set at 0.8 was
estimated as 45 subjects per group. We increased this to
60 subjects per group to maintain adequate statistical
power in case of potential dropouts.
Statistical analysis
Statistical analyses will be conducted by an independent
statistician (KM) who is not a TAU medical doctor or
CBT-IE-w/vid therapist.
 Analysis set for efficacy analysis: modified intention
to treat (ITT) set that includes all subjects who have
at least one outcome after intervention.
 If possible, data from participants who drop out will
be collected after dropout.
 Analysis for background factors: summary statistics
(frequency, mean, SD) will be calculated depending
on the characteristics of each variable.
 Primary analysis: mixed model for repeated
measures (MMRM) analysis will be applied to
the change from baseline for IBSSI-J at visit five
(for participants in the TAU alone group the time
point is defined as 6 to 10 weeks after
randomization) and visit ten (for participants in
the TAU alone group the time point is defined as
10 to 16 weeks after randomization), where
treatment, visit, treatment-by-visit interaction, and
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baseline IBSSI-J are modeled as fixed effects. T-tests
will then be conducted on the difference of adjusted
means between the groups at visit 10.
 Secondary analyses: MMRM analysis will be applied
to other continuous outcomes.
Data management and monitoring
Acquired data will be entered immediately into an Elec-
tronic Data Capture System at each center. Data review
and verification will be conducted by a person who did
not perform the initial entry. Onsite monitoring will be
conducted periodically by dedicated staff of the Data
Management division at NCNP (these staff members
are independent from this study). The Data and Safety
Monitoring Board will oversee the trial data and ethics,
with an independent chair and two independent members.
The members of the committee are independent from the
sponsor and competing interests of the present study. The
principle investigator (TA) will submit an annual progress
report to the Data and Safety Monitoring Board.
Safety
Information on serious adverse events (SAEs) will be
collected from the TAU medical doctor or CBT-IE
therapist during the intervention. Based on the Ethics
Guideline for Clinical Research (Ministry of Health,
Labour and Welfare (MHLW)), an SAE is defined as ‘an
adverse event that may lead to death or to enduring
severe impairment depending on the patient’s conditions
and circumstances’ and will include any one of the
following outcomes:
 Results in death (all deaths regardless of causal
relationship with the intervention or for which a
causal relationship with the intervention cannot be
excluded, during the intervention phase or up to
30 days after the completion of the intervention)
 Is life threatening, or places the participant at
immediate risk of death from the event as it
occurred
 Requires or prolongs hospitalization
 Causes persistent or significant disability or
incapacity
 Results in congenital anomalies or birth defects
 Is another condition which investigators judge
to represent significant hazards
Follow-up after serious adverse event
When an SAE occurs, the medical doctor will take all
necessary and appropriate measures to ensure the safety
Table 2 Schedule of assessments
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of the patient and will provide appropriate treatment
including hospital admission. The medical doctor will
immediately notify the principal investigator (TA) of
the SAE, and the principal investigator will notify all
collaborating investigators. The head investigator of
all sites will report the SAE to the relevant authorities
(Data and Safety Monitoring Board, Institutional Review
Board, and President of each center) and the Japanese
MHLW. The medical expenses will be borne by the
patient because the treatment will be supplied as a health-
care service provided under national health insurance, the
same as for usual treatment. There will be no special
financial compensation; however, any negligence on
the part of the physician may be covered by the
doctors’ liability insurance.
Ethical issues
The present study complies with the ethical guidelines
for clinical studies published by the Japanese MHLW, as
well as the ethical principles established for research on
humans stipulated in the Declaration of Helsinki and
further amendments thereto. This protocol has been
reviewed and approved by the Institutional Review Board
of the (Japanese) National Center of Neurology and Psy-
chiatry (accepted on November 29, 2017; A2017–067) and
the Ethics Committees of all four collaborating facilities.
If important protocol modifications such as changes to
eligibility criteria, outcomes, or analyses are needed for
any reason, the principal investigator (TA) will commu-
nicate this with the Institutional Review Boards.
Written informed consent will be obtained from all
participants, who will be informed that they can with-
draw from the study at any time and that their with-
drawal will never lead to refusal of any other services. A
medical doctor or a clinical psychotherapist in charge of
the informed consent process is responsible for ensuring
that informed consent is given by each patient.
Data from each participant will be handled with se-
quentially allocated numbers to maintain participant
confidentiality. All data collected in this study will be
securely stored without personal information (name,
address, etc.). Access to the data is encrypted and
limited to researchers affiliated with this study.
Dissemination
The study findings will be disseminated via publications
in peer-reviewed international journals. We will submit
annual progress reports to the MHLW and NCNP,
which are funding resources for this trial. We will also
present the findings at relevant research conferences.
Discussion
Previous studies have indicated that the standard medi-
cations (TAU), such as bulking agents and
antispasmodics, have low responsiveness [40–42] and
that many patients with IBS suffer from ongoing symp-
toms. Some meta-analyses on the efficacy of antidepres-
sants for IBS reported that they are effective in IBS
treatment [43], but several systematic reviews [44] have
indicated that the efficacy of SSRI and tricyclic antide-
pressants did not surpass bulking agents and antispas-
modics. In such circumstances, psychological treatments
such as CBT have been shown to be helpful for IBS symp-
toms [45, 46]. However, Craske et al. [15] reported that
the use of an active control leads to smaller effect sizes
than studies with TAU or wait-list designs. Therefore,
in this study we will assess the effectiveness of CBT-
IE-w/vid in addition to TAU compared to TAU alone
for improving IBS symptoms.
CBT-IE was originally developed for panic disorder
and involves exercises causing physical sensations that
mimic those experienced in a panic attack [16, 47].
Patients with IBS also have problems with physical sen-
sations such as hypervigilance and hypersensitivity to
sensations related to IBS symptoms [15]. Although the
interoceptive exposure procedure can be a promising
approach to reduce anxiety to abdominal sensation as a
perpetuating factor of IBS, it has never been studied in
the Japanese population. As a result, this procedure is
not used clinically for IBS in Japan. In this study, we will
evaluate gastrointestinal symptom-specific anxiety using
VSI and body vigilance with BVS-J as possible mediators
on the effect of CBT-IE on IBS symptoms. We will also
assess IBS specific QOL and health related QOL as
secondary outcomes. Efficacy on QOL has not been well
elucidated in the previous CBT-IE study by Craske et al.
Our study has three strengths. First, it is the first RCT
of CBT treatment for IBS in Japan. Second, we will utilize
video materials to facilitate and shorten each face-to-face
therapy session to enhance the cost-effectiveness of
psychotherapy. The amount of the time necessary for a
face-to-face therapy session was reduced from 66min
(face-to-face therapy alone) [21] to 38min (using comple-
mentary video materials) [22], and the program relies
more on self-administered management. Third, this is a
multisite RCT (five sites in Japan), which will facilitate
participant recruitment. In addition, participants recruited
from five sites will provide a more reliable representation
of the target patient population than a single-center study,
which is favorable to implementation as well.
There are some limitations to this study. The primary
endpoint in this study is a patient-reported outcome
(PRO). It is desirable to set more objective outcomes as
primary endpoints. However, currently there is no stand-
ard objective outcome for IBS that could be used as an
objective primary endpoint. Using PRO as the primary
endpoint is recommended in the guidance for clinical
trials of IBS published by the United States Food and
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Drug Administration [48]. Moreover, bias from using
PRO is expected to operate equally in both groups,
rendering any observed between-group differences
clinically meaningful. Also, this study is a non-blinded
randomized controlled trial due to the type of inter-
vention (psychotherapy). The impossibility of effec-
tively blinding participants to treatment allocation in
a CBT study also makes it impossible to control for
placebo effects. This is a general problem in all psy-
chotherapy studies [49].
Abbreviations
CBT: Cognitive behavioral therapy; CBT-IE: Cognitive behavioral therapy using
interoceptive exposure; CBT-IE-w/vid: CBT-IE with complimentary video
materials; IBS: Irritable bowel syndrome; ITT: Intention to treat; PRO: patient-
reported outcome; QOL: Quality of life; RCT: Randomized controlled trial;
SAE: Serious adverse event; TAU: Treatment as usual
Acknowledgements
The authors express their appreciation to Hideki Oi, Ph.D., Gensei Shimizu,
and Ichiko Iizuka, M.A., for their consultation regarding data management;
Koyo Higami, M.A., for help with revising part of the Japanese therapist’s
manual; Ayako Sugawara, M.A., for cooperating as a tester for the data
management system. The authors are grateful to Prof. Bruce D. Naliboff for
giving us permission to conduct the study using the CBT-IE protocol and for
supporting us to develop the Japanese version.
Funding
This study is funded by Intramural Research Grant (29-2) for Neurological and
Psychiatric Disorders of NCNP (to TA), a Grant-in-Aid for Scientific Research from
the MHLW (H29-Nanbyou-Ippan-059), and The Nakatomi Foundation (to AS).
Availability of data and materials
Not applicable as this is a protocol paper.
Open access
This article is distributed under the terms of the Creative Commons
Attribution 4.0 International License (http://creativecommons.org/licenses/by/
4.0/), which permits unrestricted use, distribution, and reproduction in any
medium, provided you give appropriate credit to the original author(s) and
the source, provide a link to the Creative Commons license, and indicate if
changes were made. The Creative Commons Public Domain Dedication
waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the
data made available in this article, unless otherwise stated.
Authors’ contributions
All authors contributed to the conception and design of this clinical trial. TA
is the primary investigator. TA, AS, SF, KY, H Kikuchi, H Kawanishi, and MF
designed the overall framework. YF and TA developed the video materials.
The initial draft manuscript was written by H Kawanishi and all authors
revised and contributed to writing the final manuscript. All authors read and
approved the final manuscript to be published.
Ethics approval and consent to participate
Ethics approval has been granted by the Institutional Review Board of the
National Center of Neurology and Psychiatry in Tokyo, Japan (accepted on
November 29, 2017; A2017–067). All participants will be informed about the
details of the trial, including the purpose, arrangement, probable risks, benefits,
and subjects’ rights and obligations. Signed informed consent will be obtained
from all participants before enrollment.
Consent for publication
The consent for publication was included in the consent to participate form.
Competing interests
The authors declare that they have no competing interests.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Author details
1Department of Behavioral Medicine, National Institute of Mental Health,
National Center of Neurology and Psychiatry (NCNP), Kodaira 187-8553,
Japan. 2Department of Psychology, Meisei University, Hino, Japan. 3Graduate
School of Medicine, The University of Tokyo, Tokyo, Japan. 4Department of
Psychosomatic Medicine, Center Hospital, National Center for Global Health
and Medicine, Tokyo, Japan. 5Department of Psychosomatic Medicine,
Kohnodai Hospital, National Center for Global Health and Medicine, Ichikawa,
Japan. 6Translational Medical Center, National Center of Neurology and
Psychiatry, Kodaira, Japan. 7Department of Biostatistics, Faculty of Medicine,
University of Tsukuba, Tsukuba, Japan. 8Department of Behavioral Medicine,
Graduate School of Medicine, Tohoku University, Sendai, Japan. 9Department
of Psychosomatic Medicine, Tohoku University Hospital, Sendai, Japan.
10Department of Psychosomatic Medicine, National Center Hospital of
Neurology and Psychiatry, Kodaira, Japan.
Received: 28 February 2019 Accepted: 16 May 2019
References
1. Kanazawa M, Endo Y, Whitehead WE, Kano M, Hongo M, Fukudo S. Patients
and nonconsulters with irritable bowel syndrome reporting a parental
history of bowel problems have more impaired psychological distress. Dig
Dis Sci. 2004;49:1046–53 https://www.ncbi.nlm.nih.gov/pubmed/15309899.
2. Sugawara N, Sato K, Takahashi I, Satake R, Fukuda S, Nakaji S, et al. Irritable
bowel syndrome and quality of life in a community-dwelling population in
Japan. Int J Psychiatry Med. 2017;53:159–70. https://doi.org/10.1177/
0091217417749791.
3. Ballou S, Bedell A, Keefer L. Psychosocial impact of irritable bowel
syndrome: a brief review. World J Gastrointest Pathophysiol. 2015;6:120–3.
https://doi.org/10.4291/wjgp.v6.i4.120.
4. Corney RH, Stanton R. Physical symptom severity, psychological and social
dysfunction in a series of outpatients with irritable bowel syndrome. J
Psychosom Res. 1990;34:483–91. https://doi.org/10.1016/0022-
3999(90)90022-V.
5. Dean BB, Aguilar D, Barghout V, Kahler KH, Frech F, Groves D, et al.
Impairment in work productivity and health-related quality of life in patients
with IBS. Am J Manag Care. 2005;11:S17–26 https://www.ncbi.nlm.nih.gov/
pubmed/15926760.
6. Longstreth GF, Wilson A, Knight K, Wong J, Chiou CF, Barghout V, et al.
Irritable bowel syndrome, health care use, and costs: a U.S. managed care
perspective. Am J Gastroenterol. 2003;98:600–7. https://doi.org/10.1111/j.
1572-0241.2003.07296.x.
7. Levy RL, Von Korff M, Whitehead WE, Stang P, Saunders K, Jhingran P, et al.
Costs of care for irritable bowel syndrome patients in a health maintenance
organization. Am J Gastroenterol. 2001;96:3122–9. https://doi.org/10.1111/j.
1572-0241.2001.05258.x.
8. Kennedy T, Jones R, Darnley S, Seed P, Wessely S, Chalder T. Cognitive
behaviour therapy in addition to antispasmodic treatment for irritable
bowel syndrome in primary care: randomised controlled trial. Bmj. 2005;331:
435. https://doi.org/10.1136/bmj.38545.505764.06.
9. Drossman DA, Toner BB, Whitehead WE, Diamant NE, Dalton CB, Duncan S,
et al. Cognitive-behavioral therapy versus education and desipramine versus
placebo for moderate to severe functional bowel disorders.
Gastroenterology. 2003;125:19–31. https://doi.org/10.1016/S0016-
5085(03)00669-3.
10. Lackner JM, Jaccard J, Keefer L, Brenner DM, Firth RS, Gudleski GD, et al.
Improvement in gastrointestinal symptoms after cognitive behavior therapy
for refractory irritable bowel syndrome. Gastroenterology. 2018;155:47–57.
https://doi.org/10.1053/j.gastro.2018.03.063.
11. Zijdenbos IL, de Wit NJ, van der Heijden GJ, Rubin G, Quartero AO.
Psychological treatments for the management of irritable bowel syndrome.
Cochrane Database Syst Rev. 2009:Cd006442. doi: https://doi.org/10.1002/
14651858.CD006442.pub2
12. Altayar O, Sharma V, Prokop LJ, Sood A, Murad MH. Psychological therapies
in patients with irritable bowel syndrome: a systematic review and meta-
Kawanishi et al. BioPsychoSocial Medicine           (2019) 13:14 Page 10 of 11
analysis of randomized controlled trials. Gastroenterol Res Pract. 2015;2015:
549308. https://doi.org/10.1155/2015/549308.
13. NICE guideline. Irritable bowel syndrome in adults: diagnosis and
Management of Irritable Bowel Syndrome in primary care. London: Royal
College of nursing London. Royal College of nursing. 2008. https://www.
ncbi.nlm.nih.gov/pubmed/21656972
14. Fukudo S, Kaneko H, Akiho H, Inamori M, Endo Y, Okumura T, et al.
Evidence-based clinical practice guidelines for irritable bowel syndrome. J
Gastroenterol. 2015;50:11–30. https://doi.org/10.1007/s00535-014-1017-0.
15. Craske MG, Wolitzky-Taylor KB, Labus J, Wu S, Frese M, Mayer EA, et al. A
cognitive-behavioral treatment for irritable bowel syndrome using
interoceptive exposure to visceral sensations. Behav Res Ther. 2011;49:413–
21. https://doi.org/10.1016/j.brat.2011.04.001.
16. Bouton ME, Mineka S, Barlow DH. A modern learning theory perspective on
the etiology of panic disorder. Psycho Rev. 2001;108:4–32. https://doi.org/10.
1037/0033-295X.108.1.4.
17. Craske MG, Treanor M, Conway CC, Zbozinek T, Vervliet B. Maximizing
exposure therapy: an inhibitory learning approach. Behav Res Ther. 2014;58:
10–23. https://doi.org/10.1016/j.brat.2014.04.006.
18. Hunt MG, Moshier S, Milonova M. Brief cognitive-behavioral internet therapy
for irritable bowel syndrome. Behav Res Ther. 2009;47:797–802. https://doi.
org/10.1016/j.brat.2009.05.002.
19. Ljotsson B, Falk L, Vesterlund AW, Hedman E, Lindfors P, Ruck C, et al.
Internet-delivered exposure and mindfulness based therapy for irritable
bowel syndrome--a randomized controlled trial. Behav Res Ther. 2010;48:
531–9. https://doi.org/10.1016/j.brat.2010.03.003.
20. Ljotsson B, Andersson G, Andersson E, Hedman E, Lindfors P, Andreewitch S,
et al. Acceptability, effectiveness, and cost-effectiveness of internet-based
exposure treatment for irritable bowel syndrome in a clinical sample: a
randomized controlled trial. BMC Gastroenterol. 2011;11:110. https://doi.org/
10.1186/1471-230X-11-110.
21. Yuki O, Satsuki K, Yoshitoshi T, et al. Development of cognitive behavior
therapy for irritable syndrome (CBT-IE) : a pilot study in Japan. Jpn J
Psychosom Med. 2016;56:630.
22. Funaba M, Kawanishi H, Fujii Y, et al. The feasibility and effectiveness of
cognitive behavioral therapy using interoceptive exposure with
psychoeducational video for irritable bowel syndrome. Meeting abstact of The
24th Congress of the Japanese Society of Behavioral Medicine; 2016. p. 43.
23. Whitehead WE, Palsson OS, Simren M. Irritable bowel syndrome: what do
the new Rome IV diagnostic guidelines mean for patient management?
Expert Rev Gastroenterol Hepatol. 2017;11:281–3. https://doi.org/10.1080/
17474124.2017.1292130.
24. Francis CY, Morris J, Whorwell PJ. The irritable bowel severity scoring
system: a simple method of monitoring irritable bowel syndrome and its
progress. Aliment Pharmacol Ther. 1997;11:395–402. https://doi.org/10.1046/
j.1365-2036.1997.142318000.x.
25. Shinozaki M, Kanazawa M, Sagami Y, Endo Y, Hongo M, Drossman DA, et al.
Validation of the Japanese version of the Rome II modular questionnaire
and irritable bowel syndrome severity index. J Gastroenterol. 2006;41:491–4.
https://doi.org/10.1007/s00535-006-1799-9.
26. Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, et al.
The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development
and validation of a structured diagnostic psychiatric interview for DSM-IV
and ICD-10. J Clin Psychiatry. 1998;59(Suppl 20):22–33 quiz 4–57. https://
www.ncbi.nlm.nih.gov/pubmed/9881538.
27. Adrian W, Jim W, Karin C. Attention training: effects on anxiety and beliefs
in panic and social phobia. Clin Psychol Psychother. 1997;4:226–32.
28. Labus JS, Bolus R, Chang L, Wiklund I, Naesdal J, Mayer EA, et al. The visceral
sensitivity index: development and validation of a gastrointestinal
symptom-specific anxiety scale. Aliment Pharmacol Ther. 2004;20:89–97.
https://doi.org/10.1111/j.1365-2036.2004.02007.x.
29. Saigo T, Tayama J, Hamaguchi T, Nakaya N, Tomiie T, Bernick PJ, et al.
Gastrointestinal specific anxiety in irritable bowel syndrome: validation of
the Japanese version of the visceral sensitivity index for university students.
Biopsychosoc Med. 2014;8:10. https://doi.org/10.1186/1751-0759-8-10.
30. Kanazawa M, Drossman DA, Shinozaki M, Sagami Y, Endo Y, Palsson OS, et
al. Translation and validation of a Japanese version of the irritable bowel
syndrome-quality of life measure (IBS-QOL-J). Biopsychosoc Med. 2007;1:6.
https://doi.org/10.1186/1751-0759-1-6.
31. Fukudo S, Kinoshita Y, Okumura T, Ida M, Akiho H, Nakashima Y, et al.
Ramosetron reduces symptoms of irritable bowel syndrome with diarrhea
and improves quality of life in women. Gastroenterology. 2016;150:358–66.
https://doi.org/10.1053/j.gastro.2015.10.047.
32. Gordon S, Ameen V, Bagby B, Shahan B, Jhingran P, Carter E. Validation of
irritable bowel syndrome global improvement scale: an integrated
symptom end point for assessing treatment efficacy. Dig Dis Sci. 2003;48:
1317–23 https://www.ncbi.nlm.nih.gov/pubmed/12870789.
33. Fukuhara S, Bito S, Green J, Hsiao A, Kurokawa K. Translation, adaptation,
and validation of the SF-36 health survey for use in Japan. J Clin Epidemiol.
1998;51:1037–44. https://doi.org/10.1016/S0895-4356(98)00095-X.
34. Beck AT, Steer RA, Brown GK. BDI-II, Beck depression inventory : manual. San
Antonio; 1996.
35. Kojima M, Furukawa TA, Takahashi H, Kawai M, Nagaya T, Tokudome S. Cross-
cultural validation of the Beck depression inventory-II in Japan. Psychiatry Res.
2002;110:291–9. https://doi.org/10.1016/S0165-1781(02)00106-3.
36. Beck AT Steer RA, Brown GK. BDI-II, Beck depression inventory: manual 2nd
edition. San Antonio, TX: Psychological Corporation; 1996.
37. Nakazato K, Shimonaka Y. The Japanese state-trait anxiety inventory: age
and sex differences. Percept Mot Skills. 1989;69:611–7. https://doi.org/10.
2466/pms.1989.69.2.611.
38. Saigo T, Takebayashi Y, Tayama J, Bernick PJ, Schmidt NB, Shirabe S, et al.
Validation of the Japanese version of the body vigilance scale. Psychol Rep.
2016;118:918–36. https://doi.org/10.1177/0033294116648139.
39. TSaK U. The relationship between cognitive control and depression in
female university students. Jpn J Health Psychol. 2003;16:31–42. https://doi.
org/10.11560/jahp.16.1_31.
40. Camilleri M, Chang L. Challenges to the therapeutic pipeline for irritable
bowel syndrome: end points and regulatory hurdles. Gastroenterology.
2008;135:1877–91. https://doi.org/10.1053/j.gastro.2008.09.005.
41. Drossman DA, Li Z, Andruzzi E, Temple RD, Talley NJ, Thompson WG, et al.
U.S. householder survey of functional gastrointestinal disorders. Prevalence,
sociodemography, and health impact. Dig Dis Sci. 1993;38:1569–80 https://
www.ncbi.nlm.nih.gov/pubmed/8359066.
42. NICE. Diagnosis and management of irritable bowel syndrome in adults in
primary care: summary of NICE guidance. Bmj. 2015;350:h1216. https://doi.
org/10.1136/bmj.h1216.
43. Ford AC, Talley NJ, Schoenfeld PS, Quigley EM, Moayyedi P. Efficacy of
antidepressants and psychological therapies in irritable bowel syndrome:
systematic review and meta-analysis. Gut. 2009;58:367–78. https://doi.org/10.
1136/gut.2008.163162.
44. Ruepert L, Quartero AO, de Wit NJ, van der Heijden GJ, Rubin G, Muris JW.
Bulking agents, antispasmodics and antidepressants for the treatment of
irritable bowel syndrome. Cochrane Database Syst Rev. 2011:Cd003460.
https://doi.org/10.1002/14651858.CD003460.pub3.
45. Hayee B, Forgacs I. Psychological approach to managing irritable bowel
syndrome. Bmj. 2007;334:1105–9. https://doi.org/10.1136/bmj.39199.679236.AE.
46. Lackner JM, Jaccard J, Krasner SS, Katz LA, Gudleski GD, Holroyd K. Self-
administered cognitive behavior therapy for moderate to severe irritable
bowel syndrome: clinical efficacy, tolerability, feasibility. Clin Gastroenterol
Hepatol. 2008;6:899–906. https://doi.org/10.1016/j.cgh.2008.03.004.
47. Lee K, Noda Y, Nakano Y, Ogawa S, Kinoshita Y, Funayama T, Furukawa TA.
Interoceptive hypersensitivity and interoceptive exposure in patients with
panic disorder: specificity and effectiveness. BMC Psychiatry. 2006;6:32.
https://doi.org/10.1186/1471-244X-6-32.
48. Kux L. Department of Health and Human Services, Food and Drug
Administration [docket no. FDA-2012-D-0146]: guidance for industry on
irritable bowel syndrome-clinical evaluation of drugs for treatment:
availability. Fed Regist 2012; 77: 32124–5. https://www.federalregister.gov/
documents/2012/05/31/2012-13143/guidance-for-industry-on-irritable-
bowel-syndrome-clinical-evaluation-of-drugs-for-treatment.
49. Button KS, Munafo MR. Addressing risk of bias in trials of cognitive
behavioral therapy. Shanghai Arch Psychiatry. 2015;27:144–8. https://doi.org/
10.11919/j.issn.1002-0829.215042.
Kawanishi et al. BioPsychoSocial Medicine           (2019) 13:14 Page 11 of 11
